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Abstract
Background: We performed a post hoc, subgroup analysis of a phase 3, randomized, double-blind, placebo-
controlled study of erenumab for prevention of episodic migraine (STRIVE) to determine the efficacy and safety of
erenumab in women with self-reported menstrual migraine.
Methods: Patients received placebo, erenumab 70 mg, or erenumab 140 mg subcutaneously once monthly during
the 6-month double-blind treatment phase of STRIVE. Women who reported history of menstrual migraine and
who were ≤ 50 years old were included in the analysis. Endpoints were change from baseline in monthly migraine
days (MMD) and monthly acute migraine-specific medication days (MSMD; among patients who took acute
migraine-specific medications at baseline), proportion of patients achieving ≥ 50% reduction from baseline in MMD,
and incidence of adverse events.
Results: Among 814 women enrolled in STRIVE, 232 (28.5%) reported a history of menstrual migraine and were
≤ 50 years old. Of the 232 patients, 214 (92%) had a baseline MMD > 5, suggesting a high proportion of women
with attacks outside of the 5-day perimenstrual window (2 days before and 3 days after the start of menstruation).
Information on “migraine days” includes (and does not discriminate between) perimenstrual and intermenstrual
migraine attacks. Between-group differences from placebo over months 4–6 for erenumab 70 mg and 140 mg
were − 1.8 (P = 0.001) and − 2.1 (P < 0.001) days for MMD and − 1.6 (P = 0.002) and − 2.4 (P < 0.001) days for acute
MSMD, respectively. The odds of having a ≥ 50% reduction from baseline in MMD over months 4–6 were 2.2
(P = 0.024) and 2.8 (P = 0.002) times greater for erenumab 70 mg and 140 mg, respectively, than for placebo.
Erenumab had an overall safety profile comparable to placebo.
Conclusion: Data from this subgroup analysis of women with menstrual migraine are consistent with data from
the overall STRIVE episodic migraine population, supporting the efficacy and safety of erenumab in women who
experience menstrual migraine.
Trial registration: ClinicalTrials.gov, NCT02456740. Registered 28 May 2015.
Keywords: Erenumab, Headache, Episodic migraine, Migraine prevention, Pure menstrual migraine, Menstrually
related migraine, Perimenstrual attacks
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Background
More than 50% of women self-report an association be-
tween migraine and menses [1]. These perimenstrual at-
tacks are commonly referred to as menstrual migraine if
they occur within a 5-day window (2 days prior to men-
struation and the first 3 days of menstruation). Menstrual
migraine attacks are particularly burdensome, as they tend
to be of longer duration [2–7] and are more severe and
disabling [2, 3, 5, 7–9] than non-perimenstrual attacks.
Furthermore, perimenstrual attacks are less responsive to
acute therapy, making them difficult to treat [2, 4, 5].
Women who experience migraine attacks with the ma-
jority of their menstrual periods (defined by The Inter-
national Classification of Headache Disorders [ICHD] 3
beta [10] as at least two of three periods) are classified into
either pure menstrual migraine (PMM; attacks that occur
only during the 5-day perimenstrual window) or menstru-
ally related migraine (MRM; attacks that occur during the
5-day perimenstrual window and at other times of the
cycle). PMM is a rare condition that affects approximately
5%–8% of women with migraine [9, 11, 12], with most
women self-reporting MRM [4]; however, the percentage
varies widely depending on the study populations and
diagnostic criteria used [2, 4, 11, 13].
There are no approved, specific preventive treatments for
menstrual migraine. It has been proposed that women who
do not respond to acute treatment options may be eligible to
receive either short-term or long-term preventive treatments
[14]. Several medications, including triptans, nonsteroidal
anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and
estrogen supplementation, have been investigated for short-
term prevention of menstrual migraine; however, these
agents may delay rather than prevent attacks [14]. Long-
term preventive treatment for menstrual migraine has been
investigated with topiramate, which reduced the frequency
but not the severity or duration of perimenstrual attacks
[15]. Continuous use of hormonal contraceptives can reduce
the severity and duration of migraine attacks [14, 16–18]. Al-
though hormonal contraceptives containing estrogens are
considered a viable treatment option for women with men-
strual migraine [19], evidence of their effectiveness is limited
[20], and they may be contraindicated because of their asso-
ciation with increased risk of stroke [21–24]. According to
the current guidelines, exogenous estrogens are contraindi-
cated in all women with migraine with aura and in women
with migraine without aura who are smokers and/or older
than 35 years of age [25–27]; estrogen-containing options
are therefore often not available to most women with mi-
graine aged 35 or older [25, 26].
The challenges associated with the treatment of men-
strual migraine emphasize the need for novel, nonhor-
monal, long-term preventive treatments. Erenumab is a
fully human monoclonal antibody that selectively targets
and blocks the canonical calcitonin gene-related peptide
(CGRP) receptor [28]. In the 6-month double-blind treat-
ment phase of the STRIVE trial of patients with episodic
migraine, erenumab at 70mg or 140mg once monthly
significantly reduced the number of monthly migraine
days (MMD) and monthly acute migraine-specific medica-
tion days (MSMD) and increased the odds of achieving
≥50% reduction from baseline in MMD [29]. Given the
burden and challenges in the treatment of menstrual mi-
graine, we performed a post hoc subgroup analysis of
STRIVE to determine the efficacy and safety of erenumab
in women with self-reported menstrual migraine.
Methods
Study design and patients
STRIVE (ClinicalTrials.gov, NCT02456740) was a phase
3, randomized, double-blind, placebo-controlled study of
erenumab in patients with episodic migraine [29]. In
brief, the study consisted of a 7-week screening phase
(including 4 weeks of baseline), a 6-month double-blind
treatment phase, a 7-month dose-blinded active treat-
ment phase, and a 3-month safety follow-up phase.
Randomization was stratified by region (North America
vs other) and prior preventive medication status (naïve
vs prior use vs concomitant use). Placebo and erenumab
70mg and 140mg were administered subcutaneously
once every month during the double-blind treatment
phase; erenumab 70mg or 140 mg were administered
during the 28-week active treatment phase.
Eligible patients were 18–65 years old with a history of
migraine with or without aura (based on medical records
and/or self-reported) for at least 12 months before
screening. Episodic migraine was defined as an average
of 4–14 migraine days per month with fewer than 15
headache days per month (in accordance with ICHD-
3) during the 3 months before screening and during
the 4-week baseline phase of the study. One concomi-
tant migraine-preventive medication was allowed fol-
lowing a protocol amendment that was introduced late
during the enrollment period. Patients were excluded if
they had no therapeutic response to > 2 migraine-
preventive treatment categories, defined as no reduction
in headache frequency, duration, or severity after adminis-
tration of the medication for at least 6 weeks at the
generally accepted therapeutic dose(s) based on the inves-
tigator’s assessment.
The study protocol was approved by the ethics com-
mittee or institutional review board at each clinical site,
and all patients provided signed informed consent before
the start of any study-related procedures. The study was
conducted in accordance with the International Council
for Harmonisation Good Clinical Practice Guidelines
and conforms to the provisions of the Declaration of
Helsinki.
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Menstrual migraine subgroups
Women were asked if they had migraine attacks that oc-
curred within a 5-day window (2 days prior to menstru-
ation and the first 3 days of menstruation) in at least 2 out
of the last 3 menstrual cycles prior to screening in accord-
ance with the criteria for menstrual migraine diagnosis
[10]. In industrialized countries, the average age for onset of
perimenopause is 47.5 years and is influenced by several
demographic, lifestyle, and biologic factors [30]. Based on
this, for the current subgroup analysis, we included menstru-
ating women aged ≤ 50 years with a self-reported history of
menstrual migraine attacks. Since the data collected did not
allow us to distinguish between women who had only men-
strual attacks (PMM) and those who had both menstrual
and non-menstrual attacks (MRM), both categories are in-
cluded under the label “menstrual migraine” in our analyses.
Endpoints
Efficacy endpoints were change from baseline in mean
MMD, change from baseline in mean monthly acute MSMD
among patients who took acute migraine-specific medica-
tions at baseline, and the proportion of patients achieving
a ≥ 50% reduction from baseline in MMD (proportion of re-
sponders). Efficacy was assessed for each monthly interval
from data collected daily using the patients’ electronic diaries;
the primary time point of assessment in the study was the
average monthly effect over months 4–6. Analysis of mi-
graine frequency–related endpoints includes all (both peri-
menstrual and intermenstrual) migraine days.
Safety was monitored throughout the study, and ad-
verse events were coded according to the Medical Dic-
tionary for Regulatory Activities version 19.0.
Statistical analysis
Change from baseline in MMD and monthly acute
MSMD was analyzed using a generalized linear mixed
effects model, which included treatment, visit, treatment
by visit interaction, stratification factors (North Amer-
ica/other and naïve/prior use/concomitant use), and
baseline value as covariates and assumed a first-order
autoregressive covariance structure; missing data were
not imputed. The proportion of responders was analyzed
using a stratified Cochran-Mantel-Haenszel test after
imputation of missing data as nonresponse. P values for
the between-group differences (erenumab 70 mg and
140 mg vs placebo) are nominal P values without multi-
plicity adjustment. Statistical significance was deter-
mined based on the comparison of the nominal P values
with a significance level of 0.05.
Results
Patient characteristics
Among 814 women enrolled in STRIVE, 232 (28.5%)
self-reported a history of menstrual migraine and
were ≤ 50 years old. Baseline characteristics were fairly
balanced among the treatment groups (Table 1).
Of the 232 women with menstrual migraine, 65 (28%)
were taking oral contraceptives/hormone therapy during
Table 1 Baseline characteristics









Age, years, median (range) 37 (20–49) 38 (21–50) 37 (19–50) 37 (19–50)
Race, n (%)
White 71 (86) 61 (90) 77 (95) 209 (90)
Black or African American 3 (4) 5 (7) 2 (3) 10 (4)
Asian 4 (5) 0 (0) 2 (3) 6 (3)
Other 5 (6) 2 (3) 0 (0) 7 (3)
Migraine with aura,a n (%) 48 (58) 35 (52) 38 (47) 121 (52)
Migraine without aura,a n (%) 71 (86) 61 (90) 72 (89) 204 (88)
Received hormonal contraception, n (%) 20 (24) 18 (26) 27 (33) 65 (28)
Treatment with migraine-preventive medication, n (%)
Naïve 50 (60) 37 (54) 48 (59) 135 (58)
Prior and/or concomitant use 33 (40) 31 (46) 33 (41) 97 (42)
Baseline phase (4 weeks)
Monthly migraine days, mean (SD) 8.6 (2.8) 8.3 (2.4) 8.4 (2.4) 8.4 (2.5)
Monthly acute migraine-specific medication days, mean (SD) 3.2 (3.5) 3.1 (3.1) 3.7 (3.6) 3.3 (3.4)
Acute migraine-specific medication use, n (%) 48 (58) 38 (56) 51 (63) 137 (59)
aBased on self-report; categories are not mutually exclusive
Abbreviations: SD standard deviation
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the study: 18 (26%) in the erenumab 70mg group, 27 (33%)
in the erenumab 140mg group, and 20 (24%) in the pla-
cebo group.
Efficacy
Change from baseline in mean monthly migraine days
During the study, both doses of erenumab resulted in
statistically significantly greater reductions vs placebo in
MMD as early as month 1 (Fig. 1). The mean MMD re-
duction over months 4–6 was − 1.4, − 3.2, and − 3.5 days
in the placebo, erenumab 70 mg, and erenumab 140 mg
groups, respectively (Table 2). Differences from placebo
were statistically significant: –1.8 (P = 0.001) and − 2.1
(P < 0.001) days for the erenumab 70mg and 140 mg
groups, respectively (Table 2).
An analysis of MMD was performed for patients who
were receiving exogenous hormones for contraception
versus those who were not receiving exogeneous hor-
mones (Table 3). Overall, the subgroup of patients
receiving exogenous hormones had similar efficacy re-
sults compared to the total population with a history of
menstrual migraine.
Change from baseline in monthly acute migraine-specific
medication days
In the subgroup of patients who were taking acute
migraine-specific medications at baseline, erenumab 70mg
and 140mg vs placebo resulted in greater reductions in
monthly acute MSMD starting at month 1; reductions were
statistically significant at every month for the 140-mg dose
group (Fig. 2). The mean reduction in monthly acute
MSMD over months 4–6 was 0.4, 2.0, and 2.8 days in the
placebo, erenumab 70mg, and erenumab 140mg groups,
respectively (Table 2). Differences from placebo were statis-
tically significant: –1.6 (P = 0.002) and − 2.4 (P < 0.001) days
for the erenumab 70mg and 140mg groups, respectively
(Table 2).
Fig. 1 Change from baseline in MMD. Data are shown as LSM with 95% CIs. The gray shaded area represents months 4–6. Abbreviations: CI,
confidence interval; LSM, least squares mean; MMD, monthly migraine days
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Proportion of patients achieving ≥50% reduction from
baseline in monthly migraine days
Both doses of erenumab vs placebo resulted in a signifi-
cantly higher proportion of patients achieving at least a
50% response at each time point except month 4 (Fig. 3).
A ≥ 50% response over months 4–6 was achieved by
25.3%, 42.6%, and 49.4% of patients who received pla-
cebo, erenumab 70 mg, and erenumab 140 mg, respect-
ively. The odds of having a ≥ 50% response over months
4–6 were 2.2 (P = 0.024) and 2.8 (P = 0.002) times greater
for the erenumab 70 and 140 mg groups, respectively,
than for the placebo group (Table 2).
Safety
Erenumab had an overall safety profile comparable to
placebo (Table 4). There were no cardiovascular adverse
events in this subpopulation of patients.







Migraine days per month
N 83 68 81
Change from baseline, LSM (95% CI) − 1.4 (− 2.2, − 0.7) −3.2 (− 4.0, − 2.4) −3.5 (− 4.3, − 2.8)
Difference from placebo, LSM (95% CI) −1.8 (− 2.9, − 0.7) P = 0.001 −2.1 (− 3.1, − 1.1) P < 0.001
Acute MSMD per month among patients taking acute migraine-specific medications at baseline
N 48 38 51
Change from baseline, LSM (95% CI) −0.4 (−1.1, 0.3) −2.0 (− 2.8, − 1.2) −2.8 (− 3.5, − 2.1)
Difference from placebo, LSM (95% CI) −1.6 (− 2.6, − 0.6) P = 0.002 −2.4 (− 3.4, − 1.4) P < 0.001
Patients with ≥ 50% reduction from baseline in migraine days per month (≥ 50% response)
N 83 68 81
n (%) 21 (25.3) 29 (42.6) 40 (49.4)
ORa (95% CI) 2.2 (1.1, 4.4) P = 0.024 2.8 (1.5, 5.5) P = 0.002
The analysis included randomized patients who received ≥ 1 dose of investigational product and had ≥ 1 postbaseline measurement during the double-blind
treatment phase. Change from baseline in MMD and monthly acute MSMD was analyzed using a generalized linear mixed effects model, which included
treatment, visit, treatment by visit interaction, stratification factors (North America/other and naïve/prior use/concomitant use), and baseline value as covariates
and assumed a first-order autoregressive covariance structure; missing data were not imputed. The proportion of responders was analyzed using a stratified
Cochran-Mantel-Haenszel test after imputation of missing data as nonresponse
Abbreviations: CI confidence interval, LSM least squares mean, MSMD migraine-specific medication days, OR odds ratio
aThe common ORs and P values were obtained from a Cochran-Mantel-Haenszel test, stratified by prior/current treatment with migraine-preventive medication
and region
Table 3 Change From Baseline in Mean Monthly Migraine Days by Hormonal Contraception Status














Monthly migraine days at
baseline, mean (SD)
9.5 (3.0) 8.5 (2.7) 8.9 (2.2) 8.3 (2.8) 8.2 (2.3) 8.2 (2.4)
Change from baseline over
months 4–6, LSM (95% CI)
−1.6 (− 3.4, 0.25) − 2.9 (− 4.8, − 1.0) − 3.9 (− 5.5, − 2.4) − 1.4 (− 2.2, − 0.6) −3.3 (− 4.2, − 2.4) −3.4 (− 4.2, − 2.5)
Difference from placebo −1.3 (− 3.9, 1.2)
P = 0.3
− 2.4 (− 4.7, − 0.1)
P = 0.045
−2.0 (− 3.1, − 0.8)
P = 0.001






The analysis included randomized patients who received ≥ 1 dose of investigational product and had ≥ 1 postbaseline measurement during the double-blind
treatment phase. Change from baseline in MMD and monthly acute MSMD was analyzed using a generalized linear mixed effects model, which included
treatment, visit, treatment by visit interaction, stratification factors (North America/other and naïve/prior use/concomitant use), and baseline value as covariates
and assumed a first-order autoregressive covariance structure; missing data were not imputed. P values for pairwise comparisons are nominal P values without
multiplicity adjustment
Abbreviations: CI confidence interval, LSM least squares mean
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Discussion
Consistent with the overall STRIVE population, prevent-
ive treatment with erenumab 70 mg and 140 mg vs pla-
cebo resulted in statistically significant improvements in
MMD and acute MSMD and achievement of ≥ 50%
response in this subpopulation of patients with a self-
reported history of menstrual migraine. The overall inci-
dence of treatment-emergent adverse events was also
consistent with the overall STRIVE population.
Because of the frequency and burden of migraine in
women with menstrual migraine, the majority qualify for
preventive treatment [31]. However, although there are
strategies for short-term prevention of menstrual mi-
graine, limited options are available for long-term pre-
vention [14]. It is, therefore, of interest that the efficacy
and safety profiles of erenumab in this subgroup were
similar to the overall episodic migraine population of
STRIVE, in which erenumab significantly reduced the
number of MMD and MSMD and increased the odds of
achieving ≥ 50% reduction from baseline in MMD [29].
A subgroup analysis of MMD among women who re-
ceived hormonal contraception suggests that exogenous
hormones do not impact the efficacy of erenumab in this
patient population; however, the sample sizes of these
subgroups were too small to draw any definitive conclu-
sions. Further investigation appears warranted, as several
studies suggest that fluctuations of ovarian steroid hor-
mone levels may modulate CGRP, with high estrogen
states being related to an increase in CGRP levels in
general, although the exact mechanistic interactions be-
tween ovarian steroid hormones and CGRP are not fully
understood [32].
The prevalence of menstrual migraine depends on
how it is defined and recorded, and there may be sub-
stantial differences in prevalence rates of menstrual mi-
graine determined by self-report. For example, in
population-based studies [11, 13], the reported preva-
lence of menstrual migraine is about 20% of women with
Fig. 2 Change from baseline in monthly acute MSMD among patients with a self-reported history of menstrual migraine who took migraine-
specific medications at baseline. Data are shown as LSM with 95% CIs. The gray shaded area represents months 4–6. Abbreviations: CI, confidence
interval; LSM, least squares mean; MSMD, migraine-specific medication days
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Fig. 3 Proportion of patients achieving ≥ 50% reduction from baseline in MMD. Data are shown as percentages. The gray shaded area represents
months 4–6. *Statistically significantly different from placebo. Abbreviations: MMD, monthly migraine days; OR, odds ratio







All treatment-emergent adverse events, n (%) 56 (67.5) 42 (61.8) 42 (51.9)
Grade 3a 5 (6.0) 2 (2.9) 3 (3.7)
Serious 2 (2.4) 2 (2.9) 2 (2.5)
Leading to discontinuation of study drug 3 (3.6) 1 (1.5) 3 (3.7)
Fatal 0 (0.0) 0 (0.0) 0 (0.0)
Adverse events in ≥2% of patients, n (%)b
Nasopharyngitis 10 (12.0) 8 (11.8) 8 (9.9)
Upper respiratory tract infection 2 (2.4) 6 (8.8) 5 (6.2)
Nausea 3 (3.6) 3 (4.4) 3 (3.7)
Influenza 1 (1.2) 2 (2.9) 3 (3.7)
Insomnia 0 (0.0) 0 (0.0) 3 (3.7)
Fatigue 1 (1.2) 2 (2.9) 2 (2.5)
Sinusitis 0 (0.0) 2 (2.9) 2 (2.5)
Vomiting 3 (3.6) 1 (1.5) 2 (2.5)
Injection site erythema 1 (1.2) 1 (1.5) 2 (2.5)
Urinary tract infection 5 (6.0) 2 (2.9) 1 (1.2)
Headache 0 (0.0) 2 (2.9) 1 (1.2)
Cardiovascular events, n (%)c 0 (0.0) 0 (0.0) 0 (0.0)
Adverse events were graded using CTCAE version 4.03. All serious adverse events were single-occurrence events
Abbreviations: CTCAE Common Terminology Criteria for Adverse Events
aThere were no grade 4 adverse events
bIn any of the treatment groups
cBased on the following search criteria: ischemic central nervous system vascular conditions, ischemic heart disease, and peripheral arterial disease
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migraine (approximately 7% of the general female popu-
lation), compared with 11% of women with migraine
when prospectively assessed in the context of clinic-
based studies [33]. The prevalence of self-reported men-
strual migraine determined in our analysis (28.5%) is
higher than that observed in clinical trials that prospect-
ively assessed menstrual migraine. Although our data on
menstrual migraine were collected in the context of a
prospective clinical trial, this finding may be due to self-
reported data that were not confirmed with headache
diaries during the study.
Our exploratory analysis is limited by our inability to
differentiate PMM and MRM, and our inability to exam-
ine the effect of treatment on intermenstrual vs peri-
menstrual migraine days. Given that the study required at
least 4 MMDs and the fact that 214 (92%) patients had a
baseline MMD> 5, it is reasonable to conclude that the
majority of women likely belonged to the MRM group, ex-
periencing both menstrual and non-menstrual migraine
attacks, although this information was not collected. The
patients categorized as having menstrual migraine in our
study have similar characteristics to “real-world” patients
with menstrual migraine, who are generally identified
based on retrospective self-report of perimenstrual mi-
graine attacks during clinical encounters with the treating
clinician rather than with prospective headache diaries.
Similar to the general population [34], approximately one-
third of patients with menstrual migraine reported that
they were taking oral contraceptives/hormone therapy
during the study, which may be an important confounder
in terms of efficacy in this subgroup of patients. In
addition, women who experience menstrual migraine may
be more likely to use continuous contraceptive/hormonal
options and may have been misclassified if they were not
currently experiencing perimenstrual attacks. Further-
more, the relatively small sample size likely contributed to
variability of effect and statistical significance at some time
points. Variability was reduced, however, by analyzing the
mean monthly efficacy over months 4–6, the primary pre-
specified analytic approach.
Conclusions
In summary, these exploratory data from a large phase 3
study of erenumab in patients with menstrual migraine
attacks (including both PMM and MRM subgroups) are
consistent with the overall STRIVE episodic migraine
population and support the efficacy of erenumab in this
specific subgroup of women.
Abbreviations
CGRP: Calcitonin gene-related peptide; ICHD: The International Classification
of Headache Disorders; MMD: Monthly migraine days; MRM: Menstrually
related migraine; MSMD: Migraine-specific medication days; PMM: Pure
menstrual migraine
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